Crossmark

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study

Crossref DOI link: https://doi.org/10.1038/s41408-023-00816-8

Published Online: 2023-03-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Saj, Fen http://orcid.org/0000-0003-0102-1789
Nisha, Yadav

Ganesan, Prasanth

Kayal, Smita

Kar, Rakhee

Halanaik, Dhanapathi

Dubashi, Biswajit
License Information

Text and Data Mining valid from 2023-03-24

Version of Record valid from 2023-03-24
More Information

Article History

Received: 2 October 2022

Revised: 5 March 2023

Accepted: 10 March 2023

First Online: 24 March 2023

Competing interests

: The authors declare no competing interests.

: The trial was approved by the institutional ethics committee (JIP/IEC/2020/059) and the Clinical Trials Registry of India (CTRI/2020/09/027547).

Document is current

Any future updates will be listed below